We’re very excited to have launched Proneurotech’s new landing page.
Proneurotech is a biopharmaceutical company backed by The Column Group focused on discovering and developing neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.
Axon degeneration is a key pathological component in many acute and chronic neurologic and ocular conditions including traumatic brain injury, stroke, peripheral neuropathies, glaucoma and other optic neuropathies, Parkinson’s disease, motor neuron disease, and multiple sclerosis.
Recent insights from the founders of Proneurotech and others have highlighted the central role of nicotinamide adenine dinucleotide (NAD) in the preservation of axons across numerous disease models, revealing several new druggable targets that drive the synthesis or consumption of this cardinal metabolite.